# US 2026/0130939 A1 · Production and use of natural killer (nk) cell-derived extracellular vesicles for treatment of cancer and infectious disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0130939 A1
- Document ID: US20260130939A1
- Status: Published application
- Kind: A1
- Application number: 19/377,990
- Filed: 2025-11-03
- Published: 2026-05-14
- Earliest claimed: 2024-11-08
- Assignees: Saint Louis University; The United States Government as represented by the Department of Veterans Affairs
- Applicants: Saint Louis University; The United States Government as represented by the Department of Veterans Affairs
- Inventors: Jacki KORNBLUTH
- Web page: https://patentgrep.com/patent/US20260130939A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/04: specific for metastasis
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/40: Regulators of development
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/96436: Granzymes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are therapeutic compositions, methods of preparing, and methods use for the treatment of infectious diseases and cancer. More specifically. Natural Killer Cell (NK Cell)-derived extracellular vesicles (EV's) are demonstrated as potent therapeutic agents that can kill tumor cells in vivo, but do not kill normal cells.

## Claims

### Claim 1

A method of preparing an NK cell exosome composition comprising:
(a) culturing an NK cell is the presence of IL-2, followed by PMA; and
(b) collecting the exosomes produced by the NK cell of step (a) using centrifugation followed by precipitation.

### Claim 2 (depends on 1)

The method of claim 1, wherein culturing comprises 18-24 hours in IL-2, followed by 4-6 hours with the addition of PMA.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein centrifugation comprises spinning supernatant of step (b) at 500 g for 5 minutes, then 2000 g for 10 minutes.

### Claim 4 (depends on 3)

The method of claim 3, further comprising passing the supernatant through a filter, such as a 0.22 μm filter.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein precipitation comprises mixing the material of step (b) with 50% w/v PEG8000 in 0.4M sodium acetate to a final concentration of 10% (⅕ dilution) and incubating for at least 24 hours at 4° C.

### Claim 6 (depends on 5)

The method of claim 5, further comprising centrifuging the incubated mixture at 3000 g for 30 minutes and collecting the pellet.

### Claim 7 (depends on 6)

The method of claim 6, further comprising resuspending the pellet in a buffered solution, such as phosphate buffered saline (PBS).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein IL-2 culturing is about 12-18 hours in duration and/or wherein PMA culturing is about 4-6 hours in duration.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claim 1-8, wherein the NK cell exosome preparation may be prepared from an NK cell from a donor, from umbilical cord blood or a NK cell line, including but not restricted to NK92 and NK3.3.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, further comprising assessing the exosome preparation for the presence of one or more of granzyme B, perforin, NKLAM, CD63 and/or LAMP-1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating a subject with cancer comprising administering to said subject an NK cell exosome preparation prepared by the method of any one of claims 1-10.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is drug-resistant, recurrent to metastatic.

### Claim 13 (depends on 11, 12)

The method of claim 11 or claim 12, wherein the cancer is acute myeloid leukemia, multiple myeloma, pancreatic cancer, or breast cancer (e.g., triple negative breast cancer).

### Claim 14 (depends on 11, 12, 13)

The method of any one of claims 11-13, wherein in the subject is human, non-human primate, or non-primate mammal.

### Claim 15 (depends on 11, 12, 13, 14)

The method of any one of claims 11-14, wherein the NK cell exosome preparation is administered more than once, such as on a chronic basis, and/or may be administered systemically, or administered intratumorally, or local or regional to a tumor.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The method of any one of claim 11-15, further comprising treating said cancer with a second anti-cancer therapy, such as radiation, chemotherapy, an immunotherapy (e.g., checkpoint inhibitor), a toxin therapy or surgery.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating a subject with an infectious disease comprising administering to said subject an NK cell exosome preparation prepared by the method of any one of claims 1-10.

### Claim 18 (depends on 17)

The method of claim 17, wherein the infectious disease may be a bacterium, a virus or a fungus.

### Claim 19 (depends on 17, 18)

The method of claim 17 or claim 18, wherein the method further comprises administering to said subject a second infectious disease therapy, such as an antibiotic, an anti-viral agent or an anti-fungal agent.

### Claim 20 (depends on 17, 18, 19)

The method of any one of claims 17-19, wherein in the subject is human, non-human primate, or non-primate mammal.

### Claim 21 (depends on 17, 18, 19, 20)

The method of any one of claims 17-20, wherein the NK cell exosome preparation is administered more than once, such as on a chronic basis, and/or administered systemically, or local or regional to a site of infection.

### Claim 22 (depends on 17, 18, 19, 20, 21)

The method of any one of claims 17-21, wherein the infectious disease is drug resistant.
